StockStorm.ai

BridgeBio Pharma, Inc.

BBIO Stock News

Latest BBIO news

Acoramidis Demonstrates Real-World Benefit Versus Tafamidis in ATTR-CM, Reducing Risk of Clinical Worsening

GlobeNewsWire · Wed, 23 Sep 2026 07:47:00 -0400

- In the first peer-reviewed, real-world, contemporary, comparative effectiveness study of TTR stabilizers in ATTR-CM using U.S. claims data, acoramidis was associated with a statistically and clinically significant 34% reduction in a composite of clinical worsening events (diuretic intensification, heart failure hospitalization, and mortality) versus tafamidis (p=0.046), supporting improved clinical stability of acoramidis over tafamidis

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire · Fri, 18 Sep 2026 16:01:00 -0400

PALO ALTO, Calif., Sept. 18, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that on September 18, 2026, the compensation committee of BridgeBio's board of directors approved equity grants to 36 new employees in restricted stock units for an aggregate of 63,009 shares of the Company's common stock. One-fourth of the shares underlying each employee's restricted stock units will vest on November 16, 2027, with one-twelfth of the remaining shares underlying each such employee's restricted stock units vesting on a quarterly basis thereafter, in each case, subject to each such employee's continued employment with the Company or one of its subsidiaries on such vesting dates.

BridgeBio Pharma: Attruby Peak Sales Set To Rise

Seeking Alpha · Thu, 10 Sep 2026 08:25:52 -0400

BridgeBio pharma has delivered multiple clinical and commercial successes, yet shares have repeatedly sold off after positive catalysts. Infigratinib's dwarfism trial outperformed the market leader, and Attruby continues to beat sales estimates, with management now guiding higher peak sales. Recent competitor setbacks and new data on Attruby's kidney benefits and hospital day reduction further strengthen BBIO's commercial outlook.

Market information is provided for research and visualization and is not investment advice.